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BACKGROUND: Accurate, individualized prognostication in patients with oropharyngeal squamous cell carcinoma (OPSCC) is vital 
for patient counseling and treatment decision making. With the emergence of human papillomavirus (HPV) as an important bio-
marker in OPSCC, calculators incorporating this variable have been developed. However, it is critical to characterize their accuracy 
prior to implementation. METHODS: Four OPSCC calculators were identified that integrate HPV into their estimation of 5-year overall 
survival. Treatment outcomes for 856 patients with OPSCC who were evaluated at a single institution from 2003 through 2016 were 
analyzed. Predicted survival probabilities were generated for each patient using each calculator. Calculator performance was as-
sessed and compared using Kaplan-Meier plots, receiver operating characteristic curves, concordance statistics, and calibration 
plots. RESULTS: Correlation between pairs of calculators varied, with coefficients ranging from 0.63 to 0.90. Only 3 of 6 pairs of 
calculators yielded predictions within 10% of each other for at least 50% of patients. Kaplan-Meier curves of calculator-defined risk 
groups demonstrated reasonable stratification. Areas under the receiver operating characteristic curve ranged from 0.74 to 0.80, 
and concordance statistics ranged from 0.71 to 0.78. Each calculator demonstrated superior discriminatory ability compared with 
clinical staging according to the seventh and eighth editions of the American Joint Committee on Cancer staging manual. Among 
models, the Denmark calculator was found to be best calibrated to observed outcomes. CONCLUSIONS: Existing calculators exhib-
ited reasonable estimation of survival in patients with OPSCC, but there was considerable variability in predictions for individual 
patients, which limits the clinical usefulness of these calculators. Given the increasing role of personalized treatment in patients with 
OPSCC, further work is needed to improve accuracy and precision, possibly through the identification and incorporation of addi-
tional biomarkers. Cancer 2019;125:68-78. © 2018 American Cancer Society. 
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INTRODUCTION
Head and neck cancer (HNC) comprises a diverse group of malignancies that arise from multiple subsites and vary 
with regard to presentation, treatment, and prognosis.1 Accurate prognostication in patients with HNC is critical to 
provide effective counseling and individualize optimal treatment. Prognostication in HNC typically is based on tumor- 
node-metastasis (TNM) characteristics as captured in traditional staging systems.2 As the prognostic importance of 
additional biomarkers and clinical features has become better appreciated, the need for improved decision-making tools 
has become apparent.3-8
This is particularly salient for patients with oropharyngeal squamous cell carcinoma (OPSCC). Our understand-
ing of the clinical behavior and management of OPSCC has evolved due to the increasing prevalence of human pap-
illomavirus (HPV)–associated disease.9 Compared with smoking-related and alcohol-related OPSCC, HPV positivity 
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is associated with an improved prognosis.10,11 Due to its 
distinct presentation and prognosis, a novel staging sys-
tem for HPV-associated OPSCC has been adopted for 
the eighth edition of the American Joint Committee 
on Cancer (AJCC) staging manual.2,12,13 Although the 
AJCC eighth edition staging system for OSPCC accounts 
for HPV status, its authors explicitly avoided the incor-
poration of additional personalized features, favoring in-
stead the more generalizable TNM framework.14 Despite 
the prognostic value added by HPV status, subsets of pa-
tients continue to demonstrate outcomes discordant with 
their disease stage. As such, there remains a need for ac-
curate risk stratification that incorporates HPV status as 
well as other personalized features.
With the goal of providing methods for individ-
ualized outcome prediction, numerous multifactorial, 
patient-specific calculators have been developed for mul-
tiple cancer types.15,16 To assist with calculator evalua-
tion, the AJCC has published criteria for the endorsement 
of any probability or risk model.17 Among the prognostic 
calculators published in recent years, several have been 
developed for OPSCC in the HPV era.18-21 Although 
these calculators incorporate additional prognostic fac-
tors such as age, smoking history, and TNM classifi-
cations in a heterogeneous manner, they all appear to 
demonstrate impressive accuracy in their respective study 
cohorts. However, to our knowledge, the generalizability, 
consistency, and accuracy of these calculators in predict-
ing outcomes for individual patients in diverse popula-
tions remain unclear. These uncertainties are critical to 
address so as to optimally implement these tools into 
clinical practice. Thus, we sought to characterize and 
compare the accuracy and precision of existing OPSCC 
individualized prognostic calculators.
MATERIALS AND METHODS
Patient Selection
Patient data collection, extraction, and analysis were ap-
proved by the institutional review board of the University 
of Michigan. Patient data were extracted from 2 overlap-
ping data sets at the University of Michigan: 1) a prospec-
tively collected epidemiologic database of patients with 
HNC6,7; and 2) a database of patients treated with radio-
therapy (RT) or chemoradiotherapy (CRT) for OPSCC.22 
Patient data that existed in both data sets were checked 
individually for agreement, and any conflicting values 
were resolved by reference to the primary medical record. 
Patients were diagnosed and treated from 2003 through 
2016 as per institutional practices, which were consistent 
with National Comprehensive Cancer Network guide-
lines. Because the selected calculators were designed to be 
used prior to any intervention, clinical information was 
analyzed, with pathological data substituted only in cases 
for which clinical information was unavailable.
Prognostic Calculator Selection
Candidate prognostic calculators were identified through 
a systematic literature search and assessed for eligibility. 
Inclusion criteria stipulated applicability to OPSCC, pro-
vision of 5-year overall survival (OS) prediction, and the 
inclusion of HPV status as determined by detection of 
HPV DNA and/or p16.
We identified 4 calculators: 1) one that was de-
veloped at the MAASTRO Clinic (“MAASTRO”)20; 
TABLE 1. Summary of Data Sets and Models for Each Calculator
Calculator
Cancers In Training 
Data Set Training Data Set Validation Data Set
Reported C-Indices 
and/or AUCs
MAASTRO20 OPSCC 168 patients, MAASTRO Clinic: 
2000-2011
189 patients, 
VUMC: 2000-2006
Training C-index: 
0.82; external 
C-index: 0.73
RTOG18 OPSCC 493 patients, multiple North 
American centers on RTOG 0129 
and 0522: 2002-2009
153 patients, 
multiple North 
American centers 
on RTOG 9003: 
1991-1997
Training C-index: 
0.76a; external 
C-index: 0.68
Erasmus21 Multiple HNC subsites Cohort size unknown, EMC: 
2006-2013
None Not available
Denmark19 OPSCC 1542 patients, eastern Denmark: 
2000-2014
None Training AUC: 0.8a
Abbreviations: AUC, area under the receiver operating characteristic curve; C-index, concordance statistic; Denmark, eastern Denmark; EMC, Erasmus 
Medical Center; HNC, head and neck cancer; MAASTRO, MAASTRO Clinic; OPSCC, oropharyngeal squamous cell carcinoma; RTOG, Radiation Therapy 
Oncology Group; VUMC, Vrije University Medical Center.
aUncorrected values; bias-corrected values are available in the corresponding published reports.18,19
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2) one that was based on data from Radiation Therapy 
Oncology Group (“RTOG”) trials18; 3) one that 
was based on patients treated in eastern Denmark 
(“Denmark”)19; and 4) one that was developed at 
Erasmus Medical Center (“Erasmus”).21,23 Table 1 sum-
marizes the data sources of each calculator, with addi-
tional details provided in Supporting Tables 1 to 4. The 
definition of HPV status varied among calculators. For 
model analysis, we applied whichever definition was 
used in the development and validation of each respec-
tive model. For example, for the MAASTRO model, 
HPV DNA was used to classify patients as HPV pos-
itive or HPV negative, regardless of p16 results. For 
the Erasmus calculator, because to our knowledge the 
method of HPV status definition has not been reported 
to date, we elected to use p16 as is recommended in 
the eighth edition of the AJCC staging manual.24 In 
our data set, HPV DNA and p16 results were discor-
dant for only 23 patients (2.7%). These patients were 
differentially classified as either HPV positive or HPV 
negative depending on the calculator being evaluated. 
Inputs for each calculator are summarized in Table 2 
and Supporting Tables S5–7. Additional details are pre-
sented in the Supporting Information.
Statistical Analysis
The predicted 5-year OS was computed for each patient 
using each calculator. Agreement between predictions 
was assessed using scatter plots and Spearman correlation 
coefficients. The ability of each calculator to risk-stratify 
patients was assessed by dividing subjects into quintiles 
(5 equally sized groups) based on their predicted risk and 
using Kaplan-Meier methods to plot their corresponding 
observed OS. The discriminatory ability of each model 
was assessed by calculating areas under the receiver oper-
ating characteristic (ROC) curve (AUCs) at 5 years25 and 
concordance statistics (C-indices).26 Absolute prediction 
accuracy was assessed by calibration plots generated using 
a “moving window” method. For this analysis, patients 
were divided into multiple overlapping risk groups with 
calculator-predicted 5-year survival probabilities within a 
moving window of 0.25.27 The average predicted 5-year 
OS for each group then was plotted against the corre-
sponding Kaplan-Meier estimates of 5-year OS.
TABLE 2. Input Factors for Each Calculator
MAASTRO RTOG Erasmus Denmark
Age Not included Dichotomized  
(≤50 y vs >50 y)
Continuous Continuous
Sex Included Not included Included Not included
Comorbidity ACE-27, dichotomized  
(none-mild vs moderate-severe)
Not included ACE-27, ordinal  
(grades 0-3)
Not included
Performance 
status
Not included ECOG (0 vs 1) Not included ECOG, ordinal 
(0-4)
Smoking status Pack-y, ordinal  
(none, moderate [1-30 pack-y], or 
heavy [>30 pack-y])
Pack-y, dichotomized 
(≤10 pack-y vs >10 
pack-y)
Not included Pack-y, 
continuous
Education Not included Dichotomized  
(≤high school vs >high 
school)
Not included Not included
Determination of 
HPV status
HPV DNA p16 Not specifieda HPV DNA and p16
Stageb Ordinal T classification and 
dichotomized N classification 
(N0-N2a vs N2b-N3)
Dichotomized T 
classification  
(T2-3 vs T4) and N 
classification  
(N0-2b vs N2c-3)
Ordinal T, N, and M 
classifications
Ordinal T and N 
classifications
Hemoglobin Continuous Dichotomized  
(≤13.5 g/dL vs >13.5 
g/dL for men, and 
≤12.5 g/dL vs >12.5 g/
dL for women)
Not included Not included
Treatment Not included Not included Receipt of chemother-
apy, dichotomized  
(yes vs no)
Categorical  
(RT, CRT, 
palliative, or no 
treatment)
Abbreviations: ACE-27, Adult Comorbidity Evaluation-27; CRT, chemoradiotherapy; Denmark, eastern Denmark; ECOG, Eastern Cooperative Oncology Group; 
Erasmus, Erasmus Medical Center; HPV, human papillomavirus; MAASTRO, MAASTRO Clinic; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group.
aTo the authors’ knowledge, the method used to define HPV status for the Erasmus calculator has not been reported to date. For this analysis of the Erasmus 
calculator, HPV status was defined using p16.
bStage herein refers to American Joint Committee on Cancer seventh edition criteria, although the RTOG calculator allows for use of the seventh or eighth 
edition.
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To handle missing covariates, we used a multiple 
imputation approach based on a multistate cure model 
(Supporting Fig. 1).28 We used the substantive model 
compatible–fully conditional specification approach, 
which involves imputing each covariate with missing 
values iteratively from a distribution proportional to the 
likelihood for the multistate cure model and a model for 
that covariate given the other covariates.29 Additional 
details regarding this novel methodology are provided in 
the Supporting Information.
TABLE 3. Patient Characteristics (N = 856)
Characteristic Value
Mean age at diagnosis, y (SD) 58.4 (9.65)
Sex, no. (%)
Male 725 (84.7)
Female 131 (15.3)
Hemoglobin, mean (SD) 13.9 g/dL (1.53)
Unknown, no. (%) 119 (13.9)
ACE-27 comorbidity, no. (%)
None 206 (24.1)
Mild 259 (30.3)
Moderate 112 (13.1)
Severe 44 (5.1)
Unknown 235 (27.4)
Smoking status, no. (%)
Never 283 (33.1)
Former 297 (34.7)
Current 271 (31.7)
Unknown 5 (0.5)
Pack-y
Mean (SD) 20.3 (25.2)
Median (range) 10 (0-150)
Unknown, no. (%) 42 (4.9)
ECOG performance status, 
no. (%)
0 409 (47.8)
1 52 (6.1)
2 1 (0.1)
Unknown 394 (46.0)
Maximum level of education, 
no. (%)
≤High school 379 (44.3)
>High school 162 (18.9)
Unknown 315 (36.8)
Race, no. (%)
White 348 (40.7)
Black 10 (1.2)
Other 2 (0.2)
Unknown 496 (57.9)
T classification (AJCC 7th), 
no. (%)
T0/Tis 0
T1 195 (22.8)
T2 284 (33.2)
T3 138 (16.1)
T4 236 (27.6)
Unknown 3 (0.3)
T classification (AJCC 8th), 
no. (%)
T0/Tis 0
T1 195 (22.8)
T2 284 (33.2)
T3 138 (16.1)
T4 236 (27.6)
Unknown 3 (0.3)
N classification (AJCC 7th), 
no. (%)
N0 110 (12.9)
N1 90 (10.5)
N2 45 (5.3)
N2a 65 (7.6)
N2b 327 (38.2)
N2c 139 (16.2)
N3 80 (9.3)
Characteristic Value
N classification (AJCC 8th), 
no. (%)
N0 108 (12.6)
N1 384 (44.9)
N2 177 (20.7)
N3 79 (9.2)
Unknowna 108 (12.6)
Clinical stage (AJCC 7th), no. 
(%)
0 0
I 18 (2.1)
II 38 (4.4)
III 98 (11.4)
IV 701 (81.9)
Unknown 1 (0.1)
Clinical stage (AJCC 8th), no. 
(%)
I 275 (32.1)
II 113 (13.2)
III 158 (18.5)
IV 65 (7.6)
Unknownb 245 (28.6)
Viral markers, no. (%)
HPV+/p16+ 394 (46.0)
HPV+/p16- 8 (0.9)
HPV+/p16 missing 93 (10.9)
HPV-/p16+ 15 (1.8)
HPV-/p16- 68 (7.9)
HPV-/p16 missing 13 (1.5)
HPV missing/p16+ 21 (2.5)
HPV missing/p16- 10 (1.2)
HPV missing/p16 missing 234 (27.3)
Treatment modality, no. (%)
CRT 651 (76.1)
RT alone 42 (4.9)
Surgery plus adjuvant CRT 33 (3.9)
Surgery plus adjuvant RT 35 (4.0)
Surgery alone 23 (2.7)
Chemotherapy alone 14 (1.6)
Palliative, unknown 58 (6.8)
Abbreviations: +, positive; -, negative; ACE-27, Adult Comorbidity 
Evaluation-27; AJCC 7th, American Joint Committee on Cancer seventh 
edition; AJCC 8th, American Joint Committee on Cancer eighth edition; 
CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; 
HPV, human papillomavirus; RT, radiotherapy; SD, standard deviation.
aThe AJCC 8th N classification for these patients was either N1 or N2.
bThe AJCC 8th group stage was unknown in these patients due to unknown 
N classification or HPV status.
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RESULTS
A total of 856 patients were identified for calculator as-
sessment. Patient and disease characteristics are summa-
rized in Table 3. The median follow-up was 61 months. 
Approximately 74% of patients and 61% of patients, re-
spectively, had at least 3 years and 5 years of follow-up, or 
died before 3 years and 5 years. Figure 1 shows the distri-
bution of predictions from the calculators (on the diago-
nal), scatter plots demonstrating the agreement between 
pairs of calculators (below the diagonal), and correlation 
coefficients between predictors (above the diagonal). The 
distributions showed similar ranges of predictions for 
each calculator, with the exception of MAASTRO, which 
tended to predict lower 5-year OS. The scatter plots and 
correlation coefficients demonstrated variable degrees of 
association between calculator pairs. The Denmark and 
Erasmus calculators demonstrated the strongest correla-
tion with each other (rho, 0.907), whereas the RTOG 
and MAASTRO calculators demonstrated the weakest 
correlation with each other (rho, 0.634). Table 4 lists the 
percentages of patients for whom each pair of calculators 
yielded predictions within 10% of each other. For only 3 
of the 6 pairings were predicted outcomes within 10% of 
each other for at least 50% of patients.
We next sought to characterize the relative accuracy 
of each calculator by assessing its ability to stratify pa-
tients into risk categories. To do this, we divided patients 
into equally sized quintile groups based on predicted 
risk and generated Kaplan-Meier plots of their observed 
outcomes. Although all calculators yielded the expected 
distribution of survival outcomes, the MAASTRO and 
RTOG calculators exhibited relatively poorer differentia-
tion of the 2 lowest risk groups (Fig. 2).
We next generated ROC curves and calculated 
AUCs and C-indices (Fig. 3). There was a range of dis-
criminatory ability among the 4 calculators, with the 
Denmark model demonstrating the best performance 
(AUC, 0.80; C-index, 0.78) and the MAASTRO cal-
culator yielding the worst (AUC, 0.74; C-index, 0.71). 
By comparison, AUCs and C-indices based on clinical 
stage alone were 0.53 and 0.51, respectively, using the 
AJCC seventh edition criteria, and were 0.72 and 0.68, 
respectively, using the AJCC eighth edition criteria (see 
Supporting Fig. 2), indicating inferior discriminatory 
ability compared with each of the 4 calculators.
We next assessed the absolute predictive accuracy, 
or calibration, of these calculators by plotting calcula-
tor-predicted versus Kaplan-Meier–estimated rates of 
5-year OS (Fig. 4). The Denmark calculator demon-
strated the best calibration whereas the MAASTRO 
calculator underestimated survival and the RTOG and 
Erasmus calculators overestimated survival for patients at 
intermediate and low risk, respectively.
DISCUSSION
Using a large patient database, we assessed individualized 
calculators designed to predict 5-year OS in patients with 
OPSCC. Although these models demonstrated reason-
able risk stratification and discriminatory abilities, we 
observed suboptimal consistency of predicted outcomes 
between calculators. In general, the AUCs and C-indices 
computed in the current analysis were lower than the 
training values and similar to or higher than the external 
cohort values previously reported for these calculators, al-
though no external AUC was provided for the Denmark 
calculator and to our knowledge no training or valida-
tion values have been published for the Erasmus one. 
AUCs and C-indices from each calculator were higher 
than those obtained from the seventh and eighth editions 
of the AJCC staging manual. The assessment of absolute 
predictive accuracy indicated that the Denmark calcula-
tor had the best calibration.
Although the OPSCC calculators exhibited rea-
sonable accuracy in the current study, the variability ob-
served among them indicates that the predicted prognosis 
for a given patient could vary substantially depending on 
which calculator is used. Communication of accurate in-
formation is vital to patient counseling and shared deci-
sion making, which has been shown to improve perceived 
quality of care and patient satisfaction.30-32 The results of 
the current study suggest that although currently avail-
able OPSCC calculators may outperform TNM staging, 
they nevertheless pose the risk of providing inaccurate 
predictions of prognosis. These results underscore an-
other important issue regarding risk prognostication and 
patient education. In addition to OS, there are numerous 
other oncologic and functional outcomes that can be pre-
dicted by individualized risk calculators.15 How to opti-
mally integrate and present different predicted outcomes 
is unclear at this time, and future work should seek to 
better define physician and patient preferences and abili-
ties to synthesize this complex information.
In addition to patient education, the accurate pre-
diction of prognosis is becoming increasingly important 
for determining treatment recommendations and for 
identifying patients in need of treatment optimization. 
This is particularly relevant to recent efforts to deinten-
sify treatment in patients with low-risk OPSCC.33-35 
Although these approaches consistently incorporate HPV 
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status, they heterogeneously account for other prognostic 
factors.36 The current study results indicate that individ-
ualized risk calculators improve prognostication beyond 
AJCC staging, even the eighth edition, which incorpo-
rates HPV status, and may represent a better method 
for selecting patients for deintensification. However, the 
observed variability among calculators suggests that the 
optimal combination of prognostic variables has not been 
identified to date. Therefore, further work is needed to 
improve prognostic calculators with which to guide indi-
vidualized treatment.
The variability among calculators was likely a func-
tion of differences in the variables included, the man-
ner in which the variables were modeled, and the data 
sources from which the variables were identified. For 
example, performance of the MAASTRO model may 
have been impaired by the inclusion of patients treated 
only with RT or CRT, and not surgery.20 However, in 
a separate analysis of the 692 patients treated with RT 
or CRT in the current study, the MAASTRO calculator 
again demonstrated inferior performance in comparison 
with the other models (Supporting Figs. 3-5, Supporting 
Table S8). In addition, the MAASTRO calculator was 
developed using the smallest training cohort and was 
the only calculator not to include age, a variable that has 
been correlated with OS in multiple studies.37
The RTOG calculator was developed using data 
from patients treated on RTOG trials 0129 and 0522, 
and validated in patients treated on the RTOG 9003 
trial.18 Although these trials included patients with HNC 
of multiple subsites, only patients with OPSCC were 
used to generate this model. This data source is advanta-
geous in that patient, treatment, and outcome data would 
be expected to be relatively homogenous, complete, and 
accurate. However, the inclusion of only those patients 
treated on clinical trials and the exclusion of patients 
with an Eastern Cooperative Oncology Group perfor-
mance status >1 may have limited generalizability.38,39 In 
Figure 1. Distribution of predicted outcomes (diagonal), scatter plots (below diagonal), and correlation coefficients (above 
diagonal) for analyzed calculators. Corr indicates correlation; RTOG, Radiation Therapy Oncology Group.
TABLE 4. Percentage of Patients With Predicted 
Survival Rates Within 10% of Each Other for Pairs 
of Calculators
RTOG Erasmus Denmark
MAASTRO 35.6% 42.6% 41.5%
RTOG 62.9% 61.8%
Erasmus 78.9%
Abbreviations: Denmark, eastern Denmark; Erasmus, Erasmus Medical 
Center; MAASTRO, MAASTRO Clinic; RTOG, Radiation Therapy Oncology 
Group.
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addition, in contrast to the other calculators, which more 
commonly modeled variables as ordinal or continuous, 
the RTOG model used dichotomization of all variables, 
which may have impaired performance.
The Erasmus model is related to a previously pub-
lished calculator based on patients treated at Leiden 
University Medical Center.40 This “Leiden” calculator 
performed poorly in an initial analysis (data not shown), 
most likely because it does not incorporate HPV status. 
Therefore, we chose to evaluate the Web-based Erasmus 
calculator, which does include HPV status and is based on 
a larger, more modern cohort treated at Erasmus Medical 
Center.21 This was the only calculator we evaluated for 
which a full description has not been published to date, 
although some cohort details have been reported in an 
analysis of patients with laryngeal cancer.23 Although the 
online interface is convenient, the lack of a corresponding 
publication describing study patients and model perfor-
mance limits its clinical usefulness. The Erasmus calcu-
lator was the only calculator derived from patients with 
HNC of multiple subsites, with different coefficients 
being assigned for each subsite. Because the prognostic 
impact of a given factor could vary among subsites, it 
is possible that this model could be less accurate than a 
model developed using only patients with OPSCC or a 
model that allowed coefficients of other factors to vary 
by subsite. In addition, this was the only calculator that 
did not include smoking status, which is an important 
prognostic factor in both patients with HPV-related and 
non–HPV-related OPSCC.7,10,41
Of the 4 calculators, the Denmark calculator 
yielded the highest AUC and C-index, and was the best 
calibrated. Although to the best of our knowledge there 
is no consensus, an AUC of ≥0.80 commonly is used to 
denote “good” discriminatory ability with a high poten-
tial for clinical usefulness.42,43 With a value of 0.80, the 
Denmark calculator met this threshold. The Denmark 
calculator was 1 of 2 models to include treatment mo-
dality and did so in a more detailed manner than the 
Erasmus calculator.
Although these calculators all include HPV status, 
there are important differences with regard to how this 
is defined for each. The MAASTRO calculator defines 
HPV positivity based on the presence of HPV DNA, 
whereas the RTOG calculator considers only p16. The 
Denmark calculator considers p16 and HPV DNA sepa-
rately. The Web site for the Erasmus calculator does not 
stipulate how HPV status should be determined and, as 
Figure 2. Kaplan-Meier plots of 5-year overall survival in risk-stratified quintile groups of equal patient numbers defined by each 
model. RTOG indicates Radiation Therapy Oncology Group.
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discussed above, there is no corresponding publication 
describing how this was defined in model building. It 
is important to consider how this variability affects the 
implementation of these calculators. HPV DNA and 
p16 positivity are correlated but do not completely over-
lap,44,45 and both tests are not performed consistently at 
all centers. The eighth edition of the AJCC staging man-
ual stipulates that p16 staining be used preferentially to 
define HPV status.24 Until it is clear that HPV DNA 
adds prognostic information beyond p16, it most likely is 
reasonable to use p16 to define HPV status when using 
these calculators, with HPV DNA being used as an al-
ternative when p16 is unavailable. If neither HPV DNA 
nor p16 status are available, caution should be exercised 
if using these calculators. For staging purposes, in the 
absence of p16 and HPV status, the eighth edition of the 
AJCC staging manual recommends staging as if the pa-
tient were HPV negative.24 A similar approach could be 
taken when using a calculator, although one also could 
consider calculating an average of predicted outcomes for 
HPV-positive and HPV-negative iterations or making an 
educated estimation of the patient’s HPV status based on 
clinical and demographic factors. If any of these is done, 
the patient should be informed of the limitations of the 
resulting prediction. This challenge can arise when any 
prognostic variable is not available, which may limit the 
usefulness of these models.
The current study is similar to our previous efforts 
to analyze individual predictors of survival in patients 
with oral cavity and laryngeal cancer.27,46 In the cur-
rent study, we found OPSCC calculators to yield higher 
AUCs and C-indices than did oral cavity and larynx 
models. This is likely due to the availability and incor-
poration of HPV, a robust biomarker, in the OPSCC 
calculators. There also were important differences in the 
data sets used for the larynx and oral cavity compared 
with OPSCC calculators. Certain of the larynx and oral 
cavity calculators were developed using the Surveillance, 
Epidemiology, and End Results database, which, al-
though large, to our knowledge lacks details regarding 
certain prognostic factors, thereby limiting its usefulness 
for calculator development.47 In contrast, the data sets 
used for the OPSCC calculators were based on institu-
tional and cooperative group databases that contained 
more detailed information regarding potential prognos-
tic variables. However, all these studies demonstrated 
substantial variability among calculators that limits their 
current value.
Figure 3. Receiver operating characteristic (ROC) curves with associated areas under the ROC and concordance statistics 
(C-indices) for each calculator. RTOG indicates Radiation Therapy Oncology Group.
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There are limitations to the current study that re-
quire consideration. Although the patient data set herein 
was reasonably comprehensive, there was some degree of 
missing data (Table 3). Because each calculator required 
different inputs, excluding patients with any missing 
variable would have reduced the number of evaluable pa-
tients substantially. As such, we elected to compensate for 
the missing covariates via a substantive model compat-
ible–fully conditional specification multiple imputation 
technique.29 Although this methodology is rigorous and 
theoretically justified, it is based on additional statistical 
models that, although fit to the data, do add additional 
modeling assumptions. A strength of this approach is 
that it uses known data to impute related missing co-
variates. Another limitation to the data set in the current 
study was that it was comprised of patients who were seen 
at a single academic institution in the midwestern United 
States. It is interesting to note that calculators derived 
from US populations were not found to be better cali-
brated to the current study patients compared with those 
developed in Europe. Regardless, it remains unclear how 
generalizable the results of the current study may be in 
relation to other institutions. It also is important to note 
that we evaluated predictions at only one time point: 5 
years. Although each calculator also predicts survival at 
other intervals, 5 years was chosen for this analysis be-
cause it is the only time point shared by all 4 models. As a 
result, we were unable to draw conclusions regarding the 
performance of these calculators in predicting survival 
prior to or beyond 5 years.
Although existing OPSCC calculators have demon-
strated reasonable predictive accuracy and superior dis-
criminatory ability compared with AJCC TNM staging, 
a lack of precision limits their usefulness for predicting 
risk in individual patients. Additional work is needed to 
improve accuracy and consistency, possibly through the 
identification of additional biomarkers.48,49 With further 
refinement, multifactorial, patient-specific risk calcu-
lators may prove beneficial for individualizing care and 
improving outcomes in individuals with OPSCC.
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